Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643728 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 12
- Study locations
NCT06643728: Active Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06643728 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 240 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06643728, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 12
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Bimagrumab
- DRUG Bimagrumab Placebo
- DRUG Tirzepatide Placebo
Study Locations (12)
Florida
- Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
- Altus Research - Lake Worth
- Suncoast Research Group - Miami
Alabama
- Pinnacle Research Group, LLC - Anniston
- Central Research Associates - Birmingham
Washington
- Eastside Research Associates - Redmond
- Rainier Clinical Research Center - Renton
California
- Diablo Clinical Research, Inc. - Walnut Creek
Hawaii
- East-West Medical Research Institute - Honolulu
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
Mississippi
- SKY Integrative Medical Center/SKYCRNG - Ridgeland
Pennsylvania
- Keystone Clinical Studies - Plymouth Meeting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What the registry record for NCT06643728 still lists
NCT06643728 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT06643728 lists 12 locations in 8 states (Florida, Alabama, Washington).
Frequently Asked Questions
What is clinical trial NCT06643728 about?
NCT06643728 is a clinical study titled "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight". The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
What is the current status of trial NCT06643728?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-10-21. Estimated completion is 2027-01.
What conditions does trial NCT06643728 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06643728?
The interventions under investigation include: Tirzepatide (DRUG), Bimagrumab (DRUG), Bimagrumab Placebo (DRUG), Tirzepatide Placebo (DRUG).
Who is sponsoring clinical trial NCT06643728?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643728 being conducted?
This trial has 12 study locations across Alabama, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06643728's enrollment target sits among peer trials
240 270th of 1053 higher than 779 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI